|
|
|
Volumn 115, Issue 1, 1994, Pages 7-15
|
|
Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
ERYTHROPOIETIN;
FLUOROURACIL;
HEMOGLOBIN;
IRON;
M PROTEIN;
PLACEBO;
RECOMBINANT ERYTHROPOIETIN;
ANEMIA;
ARTICLE;
BLEEDING;
BLOOD DONOR;
BLOOD TRANSFUSION;
BURST FORMING UNIT E;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CHRONIC KIDNEY FAILURE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
ERYTHROPOIESIS;
HEMATOCRIT;
HUMAN;
IRON DEFICIENCY ANEMIA;
MULTIPLE MYELOMA;
MYELODYSPLASIA;
NONHODGKIN LYMPHOMA;
NONHUMAN;
PERIOPERATIVE PERIOD;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SURGICAL PATIENT;
ANEMIA;
BLOOD TRANSFUSION, AUTOLOGOUS;
CLINICAL TRIALS;
ERYTHROPOIETIN;
HUMANS;
NEOPLASMS;
RECOMBINANT PROTEINS;
SURGICAL PROCEDURES, OPERATIVE;
|
|
EID: 0028011111
PISSN: 00396060
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (26)
|
|
References (0)
|
